A couple of years later, Vorinostat (Zolinza©) or suberolyanilidehydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, received FDA approval for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease [36]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.